CT for Atrial Fibrillation
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines how fibrosis, a type of heart tissue damage, affects individuals with atrial fibrillation (AF) undergoing catheter ablation. Researchers use a special heart scan, called a Cardiac CT (320-detector Computed Tomography), to measure fibrosis levels and determine if higher levels lead to more AF episodes or hospital visits. The goal is to assess whether this scan can help doctors select better treatments for AF patients. Individuals who frequently experience noticeable AF symptoms and are scheduled for ablation might be suitable candidates for this trial. As an unphased trial, it offers patients the chance to contribute to research that could enhance future AF treatments.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators or your doctor for guidance.
What prior data suggests that Cardiac CT is safe for measuring ECV in patients with Atrial Fibrillation?
Research has shown that 320-detector CT scans are generally safe for people, including those with heart devices like pacemakers. One study found that patients with these devices usually handle CT imaging well. Other research indicates that 320-slice CT scans provide clear images of the heart and blood vessels, aiding doctors in making informed decisions without causing harm. Although CT scans expose patients to some radiation, studies suggest the levels are low enough to be safe. Overall, evidence supports that this type of CT scan is a reliable and safe method for assessing heart conditions.12345
Why are researchers excited about this trial?
Researchers are excited about using 320-detector Computed Tomography (CT) for atrial fibrillation because it's a cutting-edge approach that provides detailed imaging of the heart. Unlike traditional methods that rely on standard imaging techniques, this advanced CT technology allows for precise measurement of extracellular volume (ECV), which might help in understanding the relationship between ECV expansion and the severity of atrial fibrillation. This could lead to more tailored treatments and better outcomes for patients undergoing catheter ablation, offering insights that current standard care options don't provide.
What evidence suggests that using Cardiac CT to measure ECV is effective for assessing atrial fibrillation outcomes?
Research has shown that the 320-detector CT scan effectively images the heart. It provides clear pictures of the heart's blood vessels, allowing doctors to identify issues without more invasive tests. In this trial, patients with atrial fibrillation (AF) referred for catheter ablation will undergo additional CT acquisition to measure extracellular volume (ECV). This type of CT scan accurately helps doctors check for heart disease and other problems. Its high-quality images and low radiation make it a safe and reliable tool for examining the heart in AF patients.14678
Who Is on the Research Team?
Konstantinos Aronis, MD, PhD
Principal Investigator
Johns Hopkins School of Medicine
Are You a Good Fit for This Trial?
This trial is for adults over 21 with symptomatic paroxysmal/persistent atrial fibrillation (AF), who are candidates for ablation treatment as determined by their cardiologist or electrophysiologist. They must be scheduled for a pre-procedure cardiac CT and able to give informed consent.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-procedure Assessment
Participants undergo cardiac CT scan to measure ECV as part of the standard pre-ablation routine
Procedure
Participants undergo catheter ablation for atrial fibrillation
Follow-up
Participants are monitored for recurrence of atrial fibrillation and other cardiovascular outcomes
What Are the Treatments Tested in This Trial?
Interventions
- 320-detector Computed Tomography
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
Canon Medical Systems, USA
Industry Sponsor